Business

Feliza Mirasol is the science editor for 

Articles

Bristol Myers Squibb has joined Cellares’ Technology Adoption Partnership program just as Cellares launches operations as an integrated development and manufacturing organization.

Bristol Myers Squibb Joins Cellares Program Focused on Automated Cell Therapy Manufacturing as Cellares is Launched as First IDMO

Rentschler Biopharma, CGT Catapult, and Refeyn aim to use automated and digital technologies to improve AAV manufacturing for gene therapies.

Three-Way Collaboration Between Rentschler Biopharma, CGT Catapult, and Refeyn Aims to Improve PAT for Gene Therapy Manufacturing

Danaher intends to acquire Abcam, a provider of life sciences assays and reagents, for $5.7 billion.

Danaher to Acquire Abcam in $5.7 Billion Deal

Royalty Pharma agreed to spend up to $500 million for a 5.1 to 8% royalty on net sales of Ferring’s gene therapy adstiladrin (nadofaragene firadenovec-vcng).

Royalty Pharma Places $500 Million Bet on Ferring Gene Therapy

Bright Path will develop and produce APIs for hospitals facing drug shortages in the Capstone Health Alliance.

Capstone Health Alliance and Bright Path Laboratories Enter Drug Shortage Agreement

The formulation will be used to mitigate emerging infectious diseases and public health emergencies.

Revive Therapeutics Announces Initiation of New Bucillamine Formulation Development

The deal is worth up to $36 million with an initial upfront consideration of $14 million, with an additional $22 million in contingent value rights (CVRs) that is payable upon achieving certain milestones.

LEO Pharma to Acquire Timber Pharmaceuticals

A major grant from the Bill & Melinda Gates Foundation will bolster efforts to fight the global HIV/AIDS epidemic.

Absci and Caltech Collaborate to Accelerate Affordable HIV Therapeutic Vaccine

The collaboration between Parexel and Partex is designed to leverage artificial intelligence-powered solutions to accelerate drug discovery and development.

Parexel and Partex Enter AI Alliance

Gilead and Tentarix established three multi-year collaborations to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. 

Business News